---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-033033"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:39:39.847521+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Akebia: Vafseo approved in Australia; Auryxia 2023 revenue guidance lowered to $170-175M

## Summary
- Australia's TGA approved Vafseo (vadadustat) for anemia in dialysis patients; product now approved in 35 countries.
- Akebia lowered Auryxia net product revenue guidance for 2023 to $170-175M from $175-180M due to market dynamics.
- Company plans to resubmit U.S. NDA for vadadustat by end of Q3 2023.
- Appointed Graham Ray (ex-Takeda) as VP, Key Accounts to lead U.S. launch prep and customer engagement.

## SEC filing metadata
- accession: 0001628280-23-033033
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/0001628280-23-033033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/akba-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-033033
- JSON: https://secwatch.observer/filing/0001628280-23-033033.json
- Plain text: https://secwatch.observer/filing/0001628280-23-033033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.